As good as you could hope for from this size trial. With only 24 patients, they demonstrated both engagement of the drug at site of action and change in behaviour, allowing us to be fairly confident it was the drug causing those changes in behaviour. All very promising and bodes well for PIII. No report of safety in my fairly quick glance - therefore assume not an issue. I will be buying more.
Ann: Positive BNC210 Phase 2 Anxiety Trial Results-BNO.AX, page-8
Add to My Watchlist
What is My Watchlist?